Application Note
Development of an In Vitro Model of the Human Brain Using NANOSTACKS™
Establishing a reproducible, multi-layer human brain model in NANOSTACKS™ for studying neurological disease mechanisms and testing neuroactive compounds.
Download PDFOverview
Overview
Standard 2D neuronal monocultures lack the cellular diversity and architectural organisation required to study CNS disease mechanisms or predict neuroactive compound behaviour reliably. The complexity of the human brain — multiple interacting cell types, a protective blood-brain barrier, and dynamic network activity — demands a more physiologically structured model.
This application note describes the development and characterisation of a three-dimensional, multi-cell-type human brain model using NANOSTACKS™. The system supports studies of neurological disease, neuroinflammation, compound neurotoxicity, and CNS drug transport in a format compatible with standard laboratory workflows.
Study Design
Experimental Design
Layer assembly
NANOSTACKS™ inserts assembled in 24-well plates with each insert seeded with a defined human CNS cell type. Layering order reflects anatomical organisation — endothelial cells apically, neurons basally.
Differentiation and maturation
Cultures maintained under dynamic conditions (orbital shaking) for 14–21 days to allow neuronal differentiation, network formation, and glial support cell stabilisation.
Phenotypic characterisation
Model validated by immunocytochemistry (β-III tubulin, MAP2, GFAP, Iba-1), TEER measurement (barrier integrity), and electrophysiology (spontaneous firing).
Compound testing
Test compounds applied at defined concentrations to the apical (barrier) compartment. Assays performed at acute (24 h) and sub-chronic (7–14 day) timepoints.
Model Configuration
Model Configuration and Cell Types
| Layer | Cell Type | Function |
|---|---|---|
| Apical (Layer 1) | Brain microvascular endothelial cells (BMECs) | BBB — controls compound access to neural compartments |
| Layer 2 | Astrocytes | BBB support, neuroprotection, glutamate homeostasis |
| Layer 3 | Microglia | CNS immune surveillance, neuroinflammatory response |
| Basal (Layer 4) | Neurons (SH-SY5Y / iPSC-derived) | Neuronal activity, network formation, primary toxicity target |
See the Brain MPS product page for full ordering details.
Readouts & Methods
Readouts and Methods
Structural characterisation
- Immunocytochemistry (β-III tubulin, MAP2, GFAP, Iba-1)
- Confocal fluorescence imaging (Z-stack)
- Neurite morphology and network density analysis
Barrier function
- Trans-endothelial electrical resistance (TEER)
- Lucifer Yellow permeability assay
- Tight junction protein expression (ZO-1, occludin)
Functional / electrophysiology
- MEA spontaneous network activity
- Calcium imaging (Fluo-4)
- Compound-induced firing rate changes
Toxicity and inflammation
- LDH cytotoxicity (apical/basal separately)
- IL-6, TNF-α, IL-1β cytokine ELISA
- Caspase-3 apoptosis assay
Key Findings
Key Findings
- 1NANOSTACKS™ supported stable multi-cell-type brain co-cultures for >21 days with maintained neuronal morphology and astrocytic support networks.
- 2TEER values demonstrated functional BBB formation in the apical endothelial layer, confirmed by Lucifer Yellow exclusion assay.
- 3Spontaneous neuronal network activity was detectable by MEA within 14 days, consistent with functional maturation.
- 4Compound-induced neurotoxicity was detectable at concentrations 3–5x lower than in 2D monoculture controls, indicating enhanced sensitivity of the multicellular model.
- 5Inflammatory stimuli (LPS) applied apically triggered microglial activation and cytokine release without directly affecting neuronal viability — demonstrating compartment-specific response modelling.
Significance
Why It Matters
CNS drug development has one of the highest attrition rates of any therapeutic area, in part because standard preclinical models fail to predict human-relevant neurotoxicity or CNS penetration. A multi-layer human brain model addresses key translational gaps: species differences in BBB composition, the absence of neuroinflammatory components in 2D assays, and the inability to separate barrier effects from direct neuronal toxicity.
For related multi-organ approaches, see the Multi-Organ MPS page and the Liver-Brain Axis application note.
Platform
Platform Used
This application note uses NANOSTACKS™ — Revivocell's modular microphysiological systems platform. Multi-layer inserts in SBS 24-well plates are cultured under orbital shaking to generate physiological shear stress without pumps or specialist hardware. The platform is MEA-compatible and supports extended co-cultures up to 28+ days. See What is MPS? for broader context.
Data & Figures
Experimental Data & Figures
Figures included in the full application note:
- Fig. 1 — Viability dose-response curves: SH-SY5Y monoculture vs. co-culture (methylglyoxal, IC50 comparison)
- Fig. 1B — Bar graph: SH-SY5Y viability in monocultures vs. co-cultures (mean ± SEM)
- Fig. 2 — Clomipramine testing: Hoechst + β-tubulin III immunostaining at 20X; neurite outgrowth assay results
View all figures, microscopy images, and quantification data in the embedded PDF below.
Related Resources
Related Resources
Full Application Note